A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (Gilead- NASH Cirrhosis 106)

1st August 2013 - ongoing

Status: Active

Specialism: Liver.

Team: Dr Neil Guha.

Photo Name Bio
neil-guha Dr Neil Guha Dr Neil Guha is a Clinical Associate Professor in Hepatology at the University of Nottingham. He trained at Guy's and St. Thomas's hospitals and began his postgraduate career in hepatology at St. Mary's Hospital, London. His doctoral thesis, awarded by…
Title Amount